Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries
Aardvark Therapeutics, Inc. - Common Stock
(NQ:
AARD
)
6.152
-0.588 (-8.73%)
Streaming Delayed Price
Updated: 2:37 PM EDT, Aug 18, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
43,909
Open
6.780
Bid (Size)
6.130 (200)
Ask (Size)
6.190 (300)
Prev. Close
6.740
Today's Range
6.110 - 6.860
52wk Range
3.350 - 17.94
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Kaplan Fox Encourages Investors of Aardvark Therapeutics, Inc. (NASDAQ: AARD) to Contact the Firm to Learn About Their Legal Rights
Today 10:15 EDT
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Initial Public Offering
Lawsuit
AARD Stockholder Notice: Robbins LLP Reminds Investors of the Class Action Lawsuit Against Aardvark Therapeutics, Inc.
August 17, 2026
From
Robbins LLP
Via
Business Wire
Performance
YTD
-53.4%
-53.4%
1 Month
+11.2%
+11.2%
3 Month
+41.1%
+41.1%
6 Month
-50.6%
-50.6%
1 Year
-41.1%
-41.1%
More News
Read More
Rosen Law Firm Urges Aardvark Therapeutics, Inc. (NASDAQ: AARD) Stockholders to Contact the Firm for Information About Their Rights
August 17, 2026
From
The Rosen Law Firm, P.A.
Via
Business Wire
AARD SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Reminds Aardvark (AARD) Investors of Securities Class Action Lawsuit Deadline on October 13, 2026
August 16, 2026
From
Faruqi & Faruqi, LLP
Via
Business Wire
Stockholder Alert: Robbins LLP Informs Investors of the Aardvark Therapeutics, Inc. (UWM) Class Action
August 14, 2026
From
Robbins LLP
Via
Business Wire
Aardvark Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates
August 11, 2026
From
Aardvark Therapeutics, Inc.
Via
GlobeNewswire
Unusual volume stocks in Monday's session
↗
July 13, 2026
Via
Chartmill
Top movers analysis one hour before the close of the markets on 2026-07-10: top gainers and losers in today's session.
↗
July 10, 2026
Via
Chartmill
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Aardvark Therapeutics, Inc. - AARD
June 09, 2026
From
Pomerantz LLP
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aardvark Therapeutics, Inc. - AARD
June 02, 2026
From
Pomerantz LLP
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aardvark Therapeutics, Inc. - AARD
May 26, 2026
From
Pomerantz LLP
Via
GlobeNewswire
Here are the top movers in Friday's session.
↗
May 15, 2026
Via
Chartmill
Let's uncover which stocks are experiencing notable gaps during today's session.
↗
May 15, 2026
Via
Chartmill
These stocks are moving in today's pre-market session
↗
May 15, 2026
Via
Chartmill
Wondering what's happening in today's after-hours session?
↗
May 14, 2026
Via
Chartmill
Aardvark Therapeutics Plans to Unblind HERO and OLE Data to Inform Path Forward Following FDA Clinical Hold
May 14, 2026
From
Aardvark Therapeutics, Inc.
Via
GlobeNewswire
Aardvark Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates
May 07, 2026
From
Aardvark Therapeutics, Inc.
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aardvark Therapeutics, Inc. - AARD
March 24, 2026
From
Pomerantz LLP
Via
GlobeNewswire
Aardvark Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
March 23, 2026
From
Aardvark Therapeutics, Inc.
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aardvark Therapeutics, Inc. - AARD
March 17, 2026
From
Pomerantz LLP
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aardvark Therapeutics, Inc. - AARD
March 10, 2026
From
Pomerantz LLP
Via
GlobeNewswire
AARD Investors Have Opportunity to Join Aardvark Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
March 04, 2026
From
Schall Law
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aardvark Therapeutics, Inc. - AARD
March 03, 2026
From
Pomerantz LLP
Via
GlobeNewswire
Monday's session: top gainers and losers
↗
March 02, 2026
Via
Chartmill
Let's uncover which stocks are experiencing notable gaps during today's session.
↗
March 02, 2026
Via
Chartmill
Frequently Asked Questions
Is Aardvark Therapeutics, Inc. - Common Stock publicly traded?
Yes, Aardvark Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Aardvark Therapeutics, Inc. - Common Stock trade on?
Aardvark Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Aardvark Therapeutics, Inc. - Common Stock?
The ticker symbol for Aardvark Therapeutics, Inc. - Common Stock is AARD on the Nasdaq Stock Market
What is the current price of Aardvark Therapeutics, Inc. - Common Stock?
The current price of Aardvark Therapeutics, Inc. - Common Stock is 6.152
When was Aardvark Therapeutics, Inc. - Common Stock last traded?
The last trade of Aardvark Therapeutics, Inc. - Common Stock was at 08/18/26 02:37 PM ET
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.